Barr Tamoxifen Supply Will Hold To Mid-Nov.; Firm Seeks FDA Injunction
Executive Summary
Barr will be unable to supply tamoxifen 10 mg after mid-November in the absence of court action to overrule FDA and allow the immediate launch of the firm's generic
You may also be interested in...
AstraZeneca May Market Unbranded Tamoxifen If Barr Contract Not Resumed
Nolvadex maker AstraZeneca may market its own tamoxifen generic if it cannot reach an agreement with Barr to reinstate the companies' supply and distribution agreement
AstraZeneca May Market Unbranded Tamoxifen If Barr Contract Not Resumed
Nolvadex maker AstraZeneca may market its own tamoxifen generic if it cannot reach an agreement with Barr to reinstate the companies' supply and distribution agreement
Barr’s Tamoxifen Approval Barred Until Resolution Of ANDA “Deficiencies”
Barr must resolve recently identified "deficiencies" in labeling for its tamoxifen ANDA before FDA will grant final approval of the Nolvadex generic, an Oct. 2 agency memo says